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Abstract 
 
Artemisinin has been shown to have numerous medicinal effects, most known being its 
antimalarial effects. Artesunate, artemether and other chemical analogs of artemisinin have also 
demonstrated cytostatic and cytotoxic effects in bacterial and cancer cells. Recently, artemisinin-
derivative compounds have also been demonstrated to attenuate fibrotic pathologies in various 
preclinical animal models, including those of hepatic and pulmonary fibrosis, but the 
mechanisms by which this inhibition of fibrosis occurs is not well-understood. Given the ability 
of artesunate to antagonize various fibrotic pathologies, we decided to investigate the effects of 
artesunate on a process common to all fibrotic pathologies: the emergence of the myofibroblast. 
Artesunate treatment dose-dependently attenuated expression of α-SMA, a defining molecular 
marker of the myofibroblast, in human dermal fibroblasts and inhibited activation of fibroblasts 
mediated by the profibrotic cytokine TGF-β1, which is largely responsible for the emergence of 
the myofibroblast in vivo. Immunofluorescent analysis for collagen I and collagen III 
demonstrated a marked reduction of both basal and TGF-β1-induced expression of extracellular 
matrix-associated proteins. Live cell staining for Annexin V/Propidium iodide and proliferation 
assays suggested an apoptotic mechanism is occurring in artesunate-treated cells. qRT-PCR 
analysis demonstrated artesunate-mediated downregulation of profibrotic genes including 
canonical myofibroblast markers, ECM genes, and several TGF-β receptors and ligands, and 
upregulated expression of cell cycle inhibitors and matrix-metalloproteinases. Taken together, 
these data suggest that the antifibrotic mechanisms of artesunate in vivo may be mediated by its 
antagonistic effects towards myofibroblast phenotypes or its induction of myofibroblast 
apoptosis.  
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1. Introduction  
 
1.1 Wound and scar formation 
 
Wounds in the human body have two pathways for recovery: they can either regenerate 
completely, which results in restoration of functional tissue, or they can undergo fibrosis, which 
results in the formation of a scar (Stocum, 2012). Fibrosis is generally caused by improper 
deposition of collagen by myofibroblasts and can occur both internally or externally. This 
deposition of collagen and other extracellular matrix proteins results in reduced function or loss 
of function in that particular section of tissue due to the reduced number of functional tissue-
specific cells (Stocum, 2012). For instance, in the skin, hair growth and ability to perspire at the 
location of a dermis-penetrating scar is significantly inhibited due to the loss of epidermal 
secondary structures like hair follicles and sweat glands, which can pose potential dangers for the 
victims of large burns.          
 
1.2 Fibrosis as a ubiquitous pathology 
 
Approximately 45% of deaths in the developed world can be attributed to fibrosis in some way, 
due to the wide variety of organs and tissues that can be affected by the loss of function that is a 
hallmark of fibrotic tissue (Wynn, 2007). Fibrosis is a disease that has the ability to impact many 
tissues in the body and can have devastating effects to the organism based on the location and 
severity of the fibrosis. Common models for research of this disease include pulmonary, cardiac, 
hepatic, renal and dermal fibrosis (Distler et al., 2007; Ito et al., 1998; Khalil et al., 2017; Li, Liu, 
Wang, Wang, & Chen, 2014; Roulot, Sevcsik, Coste, Strosberg, & Marullo, 1999). In this study, 
human dermal fibroblasts were selected as a preclinical model, as the skin is an accessible model 
in terms of physical accessibility for future preclinical studies and for topical treatments that 
bypass liver metabolism.  
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Figure 1: Recruitment of fibroblasts to wound site from multiple sources  
Fibroblasts can be recruited to a wound site through migration of fibroblasts from other sources, including 
from differentiation of mesenchymal progenitors, or from epithelial-to-mesenchymal transition [adopted 
from (Dolivo, Larson, & Dominko, 2017)].   
  
 
1.3 Attenuation of fibroblast activation 
Fibrosis is the result of improper wound healing in any organ, in which fibroblasts and other 
myofibroblast progenitor cells undergo activation into myofibroblasts, due to the presence of 
activating molecules such as transforming growth factor-β (TGF-β) and mechanical tension 
(Darby, Laverdet, Bonté, & Desmoulière, 2014). Fibroblasts are recruited from various sources 
after an injury (Figure 1), and are activated via TGF-β, to become a myofibroblasts (Wynn, 
2007). Myofibroblasts are responsible for the development of a scar, through their increased 
contractile activity and improper deposition of extracellular matrix proteins (Darby et al., 2014). 
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Fibroblast to myofibroblast transition is a key part of the profibrotic process (Figure 2). 
Therefore this transition is a common proposed target for many antifibrotic therapies. To this 
day, however, few of these therapies exist and scarcely few have been approved.  
 
 
Figure 2: Fibroblast-to-myofibroblast transition and myofibroblast characteristics 
Fibroblast-to-myofibroblast transition induced by TGF-β, resulting in increased presence of α-SMA-
positive stress fibers, deposition of ECM, increased contractile activity and an enlarged cell body. 
 
1.4 Therapeutic potential of Artemisia annua 
From the eastern Asian medicinal plant Artemisia annua, artemisinin and a multitude of 
chemical derivatives of have been developed that have been shown to be effective against a wide 
variety of conditions, including malaria, cancer and inflammation (Das, 2015; Shi, Li, Yang, & 
Hou, 2015). Recently one of its derivatives, artesunate, has been shown in a variety of preclinical 
studies to act as an antifibrotic, reducing the presence of profibrotic molecules, including both 
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fibrosis-associated signaling and extracellular matrix molecules (Wang, Xuan, Yao, Huang, & 
Jin, 2015).  
1.5 Proposed mechanisms of Artesunate 
Artesunate, along with artemisinin’s other chemical derivatives, artemether, arteether and 
dihydroartemisinin, contains an endoperoxide bridge in its structure, which is key to its efficacy 
and functionality in malaria patients and cancer models (Das, 2015). In these pathologies, the 
compound undergoes a Fenton reaction, in which ferrous iron breaks the endoperoxide bridge, 
and produces and causes aggregation of reactive oxygen species, which results in death of 
afflicted cells (Shi et al., 2015). It has been theorized that artesunate induces apoptosis in 
myofibroblasts, as apoptosis-associated molecules such as Fas, FasL and Caspase-3 have been 
shown to be upregulated in artesunate-treated fibroblasts in vitro (Chang-ming, Hong-xiu, & 
Xiao-fei, 2011). Our lab theorizes that this same mechanism contributes to the efficacy of 
artesunate in the reduction of fibrotic gene expression and protein levels, as many previous 
studies have shown an increase in apoptosis and a reduction of cellular growth during artesunate 
treatment of preclinical animal models and fibroblasts (Chang-ming et al., 2011; Chen et al., 
2016).  However, the effects of artesunate on profibrotic gene expression, particularly in human 
dermal fibroblasts, are not well-studied. Thus, this major qualifying project was designed to 
better understand the mechanisms through which artesunate reduces myofibroblast phenotypes 
through investigation of proliferation, apoptosis, and expression of profibrotic and 
myofibroblast-associated genes.     
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2. Materials and Methods  
 
2.1 Antibodies 
The primary antibodies used were the following: sc-32251 α-SMA, sc-8654-R Histone H3, sc-
8783 Collagen I, sc-59826 ED-A Fn, sc-271249 Collagen III (all from Santa Cruz 
Biotechnology). The secondary antibodies used were Alexafluor488-conjugated or 
Alexafluor568-conjugated (Invitrogen) for immunofluorescence and HRP-conjugated for 
Western blotting (Bio-Rad). The sc-4252 AK fluorescent annexin V (Santa Cruz) was also used.   
2.2 Cell Culture 
 
CRL-2097 and CRL-2352 human dermal fibroblasts were obtained from ATCC, and CT-1005 
human dermal fibroblasts were obtained from the University of Massachusetts Medical School 
tissue distribution program in Worcester, MA. The cultures were all maintained with 1:1 
DMEM:Ham’s F12 (Corning) supplemented with 4mM L-glutamine (Mediatech) and 10% Fetal 
Clone III (Hyclone) on Nunclon Delta tissue culture plastic (ThermoFisher) The cultures were 
incubated at 37֯C, 19% O2, 5% CO2 until treatment with artesunate or human recombinant TGF-
β1 (Peprotech). Artesunate was obtained at 100 mM concentration from Dr. Pamela Weathers. 
Cultures were treated with supplemented media one day after plating to allow for cells to adhere 
to the plate. Treated cultures were then moved to incubate at 37֯C, 5% CO2 5% O2 and were 
harvested after four days unless otherwise noted.  
2.3 SDS-PAGE and Western Blotting 
 
Samples were prepared by washing in DPBS and snap-freezing cell pellets in liquid nitrogen and 
storing at -80 ֯C for use at time of experiment. Pellet were resuspended in protein lysis buffer and 
sonicated. A Bradford assay was performed to determine the protein concentration of each 
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sample.  5X lamelli dye was added to each sample and the samples were boiled at 100 ֯C for five 
minutes. Equal amounts of protein for each sample were separated on an SDS-PAGE gel and 
transferred onto a PVDF membrane (Millipore) in a semi-dry apparatus (GE Healthcare). The 
membrane was blocked in 5% fat-free dry milk in TBS-T buffer for one hour and incubated 
overnight in a pre-determined dilution of primary antibody in 1% fat-free dry milk in TBS-T. 
After washing, the membrane was incubated in a 1:5000 HRP-conjugated secondary antibody in 
the 1% fat-free dry milk/TBS-T solution for two hours. The membrane was washed three times 
with TBS-T, then visualized using a ChemiDoc XRS system (Bio-Rad) and developed with 
SuperSignal West Dura Extended Duration Substrate (ThermoFisher).        
2.4 Florescence microscopy and flow cytometry 
 
Cells were plated in VisiPlate 24-well plates (Perkin Elmer) and grown in the presence or 
absence of artesunate and TGF-β (Peprotech). The cells were washed with DPBS and fixed with 
ice-cold methanol at room temperature for 20 minutes with agitation then permeabilized with 1.5 
M HCl for 30 minutes at RT with agitation. The cells were then blocked with 5% BSA in TBST 
for 30 minutes with agitation and treated with 250 μL primary antibody, diluted in 1xPBS-
Tween overnight at 4 ֯C with agitation (dilution specific to primary antibody). Cells were then 
treated with 250 µL of 1:500 dilution of Alexa Fluro-conjugated secondary antibody in PBS-T 
for 30 minutes in the dark with agitation. Cells were then washed three times for five minutes 
with PBS-T then treated with 500ng/mL Hoechst 33342 in PBS-T (ThermoFisher) for 15 
minutes. Cells were washed an additional two times for five minutes with PBS then imaged on 
Axiovert (Zeiss) with identical exposure times and setting between control and treatment. 
Alternatively, cells were stained for FITC-annexin V/PI according to manufacturer’s protocols 
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and analyzed on an Axiovert 200M or an Accuri C6 flow cytometer (BD Biosciences) (Figure 
2). 
 
Figure 3: Annexin V/Propidium iodide flow cytometry  
Figure shows a healthy fibroblast, compared to a fibroblast with increasing levels of fluorescent Annexin 
V-conjugated to FITC bound to the phosphatidylserine localized on the surface, characteristic of apoptotic 
cells. The propidium iodide can enter the nucleus of dead cells, fluorescing red and increasing along the 
x-axis. 
 
 
2.5 RNA isolation and qRT-PCR 
Samples were prepared by washing pellets in DPBS and snap-freezing cell pellets in liquid 
nitrogen and stored at -80 ֯C until time of the experiment. RNA was isolated using the E.Z.N.A. 
RNA Isolation Kit (Omega Bio-Tek) and the concentration of the isolated RNA was measured 
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using the Nanodrop 2000 (Thermo Scientific). The RNA was then converted to cDNA in 20 uL 
reactions using SuperScript VILO Master Mix (ThermoFisher). After conversion to cDNA, the 
samples were processed in 25 uL PCR reactions with PowerUP SYBR Master Mix Reagent and 
primers from Table 1. The PCR reactions were performed using the following procedure: 50֯C 
for 2 minutes, 95֯C for two minutes, then 40 cycles of denaturing at 95 ֯C for 15 seconds and 
anneal/extend at 60 ֯C for 1 minutes.  
Table 1: Primer sequences for qRT-PCR 
Gene 
name 
Protein encoded Forward primer (5’-3’) Reverse primer (5’-3’) 
Amplicon 
size (bp) 
ACTA2 α-SMA 
ACTGCCTTGGTGTGTGACAA  
120 
 CACCATCACCCCCTGATGTC 
CNN1 Calponin 
AGGTTAAGAACAAGCTGGCCC  
113 
 GAGGCCGTCCATGAAGTTGT 
TAGLN SM22α 
CACAAGGTGTGTGTAAGGGTG  
132 
 GGCTCATGCCATAGGAAGGAC 
CCN2 CTGF 
GTGCCTGCCATTACAACTGTC  
98 
 TCTCACTCTCTGGCTTCATGC 
ED-A Fn Fibronectin (ED-A) 
CAGTGGAGTATGTGGTTAGTGTC  
119 
 GTGACCTGAGTGAACTTCAGG 
Col1A1 Collagen 1 (α1) 
GTCAGGCTGGTGTGATGGG  
182 
 GCCTTGTTCACCTCTCTCGC 
Col1A2 Collagen 1 (α2) 
CTGGAGAGGCTGGTACTGCT  
62 
 AGCACCAAGAAGACCCTGAG 
Col3A1 Collagen III (α1) 
GGACACAGAGGCTTCGATGG  
190 
 CTCGAGCACCGTCATTACCC 
MMP1 
Matrix 
metalloproteinase 1 
GCATATCGATGCTGCTCTTTC  
110 
 GATAACCTGGATCCATAGATCGTT 
MMP3 
Matrix 
metalloproteinase 3 
ACCTGACTCGGTTCCGCCTG  
71 
 GTCAGGGGGAGGTCCATAGAGGG 
MYOCD Myocardin 
AGAGGCCATAAAAGGTAACCAGG  
116 
 GGGGGTCTTCACTTCGAGTC 
TGFB1 TGF-ϐ1 
CATTGGTGATGAAATCCTGGT  
110 
 TGACACTCACCACATTGTTTTTC 
TGFB2 TGF-ϐ2 
GAGCGACGAAGAGTACTACG  
89 
 TTGTAACAACTGGGCAGACA 
TGFBR1 TGF-ϐR1 
GCAGACTTAGGACTGGCAGTAAG  
104 
 AGAACTTCAGGGGCCATGT 
TGFBR2 TGF-ϐR2 
TGGACCCTACTCTGTCTGTG  
72 
 CTGGAGCCATGTATCTTGCAG 
TGFBR3 Betaglycan 
CTGGTGTGGCATCTGAAGAC  
79 
 GGACCACAGAACCCTCAGAC 
CDKN1A p21 
CACTGTCTTGTACCCTTGTGCC    
148 
 TTCCTCTTGGAGAAGATCAGCCG    
CDKN2A p16 
GAGCACTCACGCCCTAAGC  
139 
 AGTGTGACTCAAGAGAAGCCAG 
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MLK2 MRTFB 
GGTGCTAAGAAAGAGAATGTAAGAC  
261 
 CAACAGGGAGTGTAAGACGC 
SMAD7 Smad7 
CTGTGTTGCTGTGAATCTTACG  
120 
 CATCGGGTATCTGGAGTAAGG 
ITGA11 Integrin alpha 11 
GGTCTGTAAAAGATGTGGTGGAA  
110 
 CTTCTGGAAAGCCTCTGAGC 
IL-6 Interleukin-6 
GATGAGTACAAAAGTCCTGATCCA  
130 
 CTGCAGCCACTGGTTCTGT 
GAPDH GAPDH 
GAGTCCACTGGCGTCTTCAC  
119 
 TTCACACCCATGACGAACAT 
 
2.6 Proliferation assay  
Sample were prepared seeding CRL-2097 human dermal fibroblasts at a density of 2000 
cells/well in a tissue culture-treated 96 well plate and treated for four days prior to the assay. For 
the resazurin assay, media was aspirated and 100 µL of fresh media was added to each well. 
Twenty microliters of 6x (0.15 mg/mL) resazurin solution was added to each well. Cells were 
incubated for two hours at 37֯C and the fluorescence was read at excitation/emission of 
544nm/590nm on a Victor 1420 multilabel counter (Perkin Elmer). Proliferation rates were 
estimated by averaging replicates and calculating relative fluorescence of treated condition to the 
control.  
3. Results 
 
3.1 Artesunate is effective in reducing α-SMA in human dermal fibroblasts and can 
antagonize TGF-β-induced fibroblast activation 
 
As smooth muscle alpha actin (α-SMA) is one of the key functional markers that defines 
myofibroblast phenotypic identity (Figure 1), this was the chosen target to determine whether 
artesunate was able to antagonize profibrotic phenotypes in human dermal fibroblasts. 
Artesunate did indeed dose-dependently decrease protein expression of α-SMA, when compared 
to α-SMA expression of the negative control and TGF-β positive control (Figure 4a, 4b). The 50 
μM concentration of artesunate was chosen for use moving forward. To confirm that this effect 
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was not idiosyncratic and did not affect only the CRL-2097 human dermal fibroblast line, two 
other lines of human dermal fibroblasts, CRL-2352 and CT-1005, were also examined and 
showed qualitiatively similar decreases α-SMA protein expression when treated with artesunate 
(Figure 4b). Each cell line was co-treated with artesunate and TGF-β, and artesunate 
successfully antagonized TGF-β-mediated α-SMA expression as well. Immunofluorscent 
analysis of CRL-2097 fibroblasts for α-SMA showed a decrease in α-SMA protein expression in 
the artesunate-treated fibroblasts. Together, these data suggest that artesunate has the ability to 
antagonize fibroblast activation by TGF-β in multiple fibroblast lines, due to its ability to 
antagonize α-SMA expression.   
 
Figure 4: Artesunate-induced reduction of α-SMA expression  
 (a) CRL-2097 human dermal fibroblasts were cultured under control conditions or in the presence of 
indicated concentration of artesunate and analyzed at day 4. Protein lysates were examined via Western 
blotting for α-SMA and with Histone H3 as a loading control. (b) CRL-2097, CRL-2352 and CT-1005 
human dermal fibroblasts were cultured under control conditions or in the presence of 50 μM artesunate 
and/or 10 ng/mL TGF-β1, and analyzed at day 4. Protein lysates were examined via Western blotting for 
α-SMA and with Histone H3 as a loading control.  
 
3.2 Artesunate qualitatively reduces expression of extracellular matrix proteins 
Another hallmark of myofibroblasts and a key indicator of fibrosis is the accumulation of 
extracellular matrix proteins, such as collagen I, collagen III and ED-A fibronectin (Figure 1). 
Treatment of human dermal fibroblasts with artesunate results in a substantial decrease that was 
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observed in both collagen I and collagen III protein expression between the untreated fibroblasts, 
TGF-β-treated positive control and the artesunate-treated cells. In the co-treatments of artesunate 
and TGF-β, both collagen I and collagen III expression is attenuated, when compared to control 
fibroblasts (Figure 5b, 5c), which suggests that artesunate can antagonize TGF-β-mediated 
increases in collagen expression. There was no change observed in ED-A Fn expression (Figure 
5d). Taken together, it can be determined that artesunate decreases transition of fibroblasts to 
myofibroblasts, as it attenuates collagen I and collagen III extracellular matrix deposition.    
 
Figure 5: Artesunate-induced decrease in extracellular matrix-associated proteins  
CRL-2097 human dermal fibroblasts were cultured in control conditions or in the presence of 50 μM 
artesunate, 10 ng/mL TGF-β 1or both, and analyzed at day 4. Fibroblasts were fix and stained for (a) α-
SMA, (b) Collagen I, (c) Collagen III or (d) ED-A Fibronectin. DNA was stained with Hoechst. Scale bar 
= 100μm.   
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3.3 Artesunate downregulates transcription of fibrosis-associated genes   
To confirm that the reduction of fibrosis-associated proteins resulting from downregulation of 
gene expression at the transcriptional level, qRT-PCR was performed. It was determined that 
many of the genes that encode fibrosis-associated proteins were downregulated (Figure 6). This 
includes several major hallmark proteins of myofibroblasts, including ACTA2, TAGLN, MYOCD 
and CNN1, which encode α-SMA, SM22α, pro-myogenic transcription factor myocardin and 
calponin, respectively. Extracellular matrix genes, such as a COL1A1, COL1A2 and COL3A1 
were found to be downregulated, along with the significant upregulation of several genes 
associated with the degradation of fibrillary collagens, MMP1 and MMP3 (Figure 6). A 
significant downregulation was also detected in the gene encoding major profibrotic 
inflammatory cytokine IL-6, profibrotic CCN2, which encodes CTGF, and in ITGA11, an 
integrin that has been shown to be necessary for fibroblast activation (Rodriguez et al., 2009), 
(Bansal et al., 2017). Pro-myofibroblastic transcription factor SRF is also downregulated 
significantly, as it has been shown that inhibition of these protein is effective in reducing scarring 
in preclinical models (Yu-Wai-Man et al., 2017). Several genes encoding profibrotic TGF-β 
ligands and receptors are also downregulated, including TGFB2 and TGFBR1. Taken together, 
these data suggest that artesunate treatment antagonizes profibrotic gene expression, inhibits 
fibroblast activation, as well as increases expression of cell cycle inhibitors. 
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Figure 6: Transcriptional analysis of fibrosis-associated genes 
CRL-2097 human dermal fibroblasts were cultured in control conditions or in the presence of 50μM 
artesunate and harvested at day 4. Gene expression levels of artesunate-treated fibroblasts were determined 
relative to that of control fibroblasts using qRT-PCR. GAPDH was used as an internal control. Fold change 
was calculated using the ∆∆Ct method (Livak & Schmittgen, 2001). Statistical significance was determined 
by a two-tailed t-test per gene. n=4-5. Error bars=standard deviation. *p<.05, **p<.01, ***p<.001, 
****p<.0001. 
 
3.4 Artesunate is associated with a decrease in proliferation  
A previous report detailed artesunate-induced apoptosis in human embryonic lung fibroblasts 
(Chang-ming et al., 2011). This report, paired with observation of reduced cell density of 
artesunate-treated fibroblasts compared to control fibroblasts (Figure 5) and a significant 
upregulation in cell cycle inhibitor genes CDKN1A and CDKN2A, suggested that artesunate may 
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impact fibroblast proliferation. Considering these data, a resazurin metabolic assay to measure 
proliferation confirmed that there is a significant decreased cellular metabolism in the artesunate-
treated fibroblasts (Figure 7). Taken together, these data suggest artesunate-mediated inhibition 
of growth, based on the upregulation of key cell cycle inhibitors and the overall decreased 
growth.    
 
Figure 7: Analysis of proliferation in artesunate-treated human dermal fibroblasts 
CRL-2097 human dermal fibroblasts were cultured in control conditions or in the presence of 50μM 
artesunate and assayed at day 4. Samples were assayed in each respective well with resazurin solution. 
Fluorescence was read at excitation/emission of 544nm/590nm. Proliferation rates were estimated by 
averaging replicates and calculating relative fluorescence of each condition to the control. Error bars = 
standard deviation. Statistical significance was determined with student’s t-test. N = 4 biological 
replicates/condition, **** = p<0.0001 
 
3.5 Artesunate induces apoptosis in human dermal fibroblasts  
Considering the previous data and the hypothesis of an apoptotic-mediated mechanism, the next 
logical step was to measure fibroblast apoptosis induced by artesunate treatment. Live cell 
fluorescent imaging for Annexin V/PI qualitatively confirmed an increase in apoptotic death in 
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artesunate-treated fibroblasts compared to control fibroblasts (Figure 8). It should also be noted 
that in the phase view of the fluorescence images, there is a notable reduction in cell density 
from the artesunate-treated fibroblasts, as compared to the control fibroblasts.  
 
Figure 8: Live-cell staining for apoptotic markers 
CRL-2097 human dermal fibroblasts were cultured in control conditions or in the presence of 50μM 
artesunate and assayed at day 4. Samples were live-stained with FITC-Annexin V/Propidium iodide and 
imaged on the Axiovert 200M (Zeiss).  
 
 
Propidium iodide and annexin V-FITC fluorescence were quantified by flow cytometry, which 
showed that artesunate-treated cells were had significantly higher median PI and annexin V 
fluorescence compared to control cells (Figure 9), suggesting that the cell death induced by 
artesunate was mediated at least in part by apoptotic mechanisms. Apoptotic fibroblasts treated 
with the highly cytotoxic chemotherapeutic agent vinblastine sulfate were used as a positive 
control. Considering these data, it has been shown that artesunate effectively reduces 
proliferation of profibrotic myofibroblasts and induces apoptosis of myofibroblasts. 
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Figure 9: Flow cytometry quantification of annexin V/PI in human dermal fibroblasts 
Samples were assayed for Annexin V/Propidium iodide flow cytometry and the median fluorescence 
relative to the control was calculated. Error bars = standard deviation. Statistical significance was 
determined with an ANOVA analysis and post-hoc Tukey’s test. n = 2 biological replicates/condition. 
**p<.01, ****p<.0001.  
        
 
4. Discussion  
The development and presence of myofibroblasts is a hallmark of fibrosis in all tissues, and 
represents a potential therapeutic target for fibrosis-associated diseases and prevention of 
scarring. These data demonstrate that artesunate targets myofibroblasts by antagonizing 
fibroblast activation and deposition of types I and III collagen, resulting a decrease in the 
expression of canonical myofibroblast marker α-SMA (Figure 4-5). Artesunate treatment also 
results in decreased profibrotic gene expression, associated with downregulation of 
myofibroblast markers, and other profibrotic genes, including genes associated with TGF-β 
signaling, a central regulator of fibrosis. Among other target genes, TGF-β induces expression of 
type 1 collagen (Ignotz & Massague, 1986) and inhibits expression of MMP1 (White, Mitchell, 
 
23 
& Brinckerhoff, 2000) and MMP3 in fibroblasts (Kerr, Miller, & Matrisian, 1990), whereas these 
data demonstrate that artesunate downregulates type 1 collagen and upregulates MMP1 and 
MMP3. Paired with the qRT-PCR data that suggest artesunate downregulates several TGF-β 
receptors and ligands, these data suggest that artesunate may inhibit TGF-β activity, which is 
significant, as TGF-β can be responsible for the fibroblast-to-myofibroblast transition (Meng, 
Nikolic-Paterson, & Lan, 2016). 
These data also demonstrate that artesunate increases expression of cell cycle inhibitor genes, 
(Figure 6) reduces proliferation (Figure 7), and induces apoptosis (Figure 8, Figure 9) in 
fibroblasts. Previous literature has shown that artesunate increases p53 expression in rat primary 
hepatic stellate cells, known myofibroblast progenitors in liver fibrosis, resulting in the induction 
of growth arrest and apoptosis (Longxi, Buwu, Yuan, & Sinan, 2011). Other studies propose 
inhibition of the PI3K/Akt pathway as a possible means of decreasing proliferation in airway 
smooth muscle cells and murine lung tissue (Cheng et al., 2011; Tan et al., 2014). Taken together 
these data suggest that the antifibrotic effects of pharmacologic artesunate likely proceed at least 
in part via downregulation of profibrotic genes in myofibroblasts and myofibroblast progenitors, 
as well as via induction of myofibroblast apoptosis.  
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